Similarly, tyrphostin AG-1478, a selective EGFR-TKI, provide a potential therapeutic approach for cisplatin-resistant LC patients by inhibiting MMP-9 expression (53). This evidence concerns the gene MMP9 and laryngotracheoesophageal cleft.